Zhaoke Ophthalmology Limited

6622

KYG989M51017

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:22 10/05/2024 pm IST			5-day change	1st Jan Change
1.56 ^HKD	+2.63%		-0.64%	-60.51%

29/04	Zhaoke Ophthalmology Shrinks Loss in 2023	MT
08/04	Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	CI

Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director

April 08, 2024 at 03:42 pm IST

Zhaoke Ophthalmology Limited announced that with effect from April 8, 2024, Mr. Chen Yu has resigned as a non-executive Director in order to devote more time to his other work arrangements.

Latest news about Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Shrinks Loss in 2023	29/04	MT
Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director	08/04	CI
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea	29/01	MT
Zhaoke Ophthalmology's Investigational New Drug Applications for Pupil-Modulating Eye Drops Given Green Light by Chinese Regulator	24/01	MT
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia	24/01	CI
Zhaoke Ophthalmology Limited Announces Executive Changes	27/11	CI
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan	14/11	MT
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study	13/23/13	MT
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China	13/23/13	CI
Zhaoke Ophthalmology Enlists Patients for 2 Drug Trials; Will Refile NDA for Eye Gel	03/23/03	MT
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel	03/23/03	CI
Zhaoke Ophthalmology's Loss Widens in H1	24/23/24	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Zhaoke Ophthalmology Concludes Phase III Trial of Myopia Medication	10/23/10	MT
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial	09/23/09	CI
Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer for the Treatment of Dry Eye Disease	09/23/09	CI
US FDA Approves New Drug Application of Zhaoke Ophthalmology's Eye Drops for Nearsightedness; Shares Surge 12%	07/23/07	MT
Zhaoke Ophthalmology Partner Achieves Positive Top-Line Results from Eye Drop's Phase 3 Trial	26/23/26	MT
Zhaoke Ophthalmology Loss Narrows in 2022	27/23/27	MT
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea	27/23/27	MT
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Zhaoke Ophthalmology Limited Enters into Distribution Agreement with Kwangdong Pharmaceutical to Commercialize NVK002 in South Korea	27/23/27	CI
Lee’s Pharmaceutical Holdings Warns of Plunge in 2022 Profit	21/23/21	MT
Zhaoke Ophthalmology Gets Nod for Marketing of Eye Drop	21/23/21	MT

Chart Zhaoke Ophthalmology Limited

Duration

Period

More charts

Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Companyâs products include innovative drugs and generic drugs. The Company âs products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.443 CNY

Average target price

7.1 CNY

Spread / Average Target

+392.23%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHAOKE OPHTHALMOLOGY LIMITED	-60.51%	109M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals